Correction: GlucoMedix®, an extract of Stevia rebaudiana and Uncaria tomentosa, reduces hyperglycemia, hyperlipidemia, and hypertension in rat models without toxicity: a treatment for metabolic syndrome (BMC Complementary Medicine and Therapies, (2022), 22, 1, (62), 10.1186/s12906-022-03538-9)

Villegas Vílchez L.F.; Ascencios J.H.; Dooley T.P. · BMC Complementary Medicine and Therapies (2022) · DOI: 10.1186/s12906-022-03708-9

Resumen

Following publication of the original article [1], the authors reported an error in Table 8 and Fig. 8. The Table 8 reported for the glucose levels (Alloxaninduced) of GlucoMedix® treatments was incorrect. However, the correct data set reveals that the results are similar to those reported. The percentage of the chemically induced maximum level minus the uninduced level at 28 days (as displayed in Fig. 8) is 62.0 % at 250 mg/kg (vs 36.4 % as reported), 16.3 % at 500 mg/kg (vs 13.5 % as reported), and 0.8 % at 1,000 mg/kg (vs -2.6 % as reported), and the Glibenclamide 10 mg/kg positive control should be -1.2 % (vs -5.6 % as reported). Thus, the IC50 value for glucose levels with GlucoMedix® is between 250 and 500 mg/kg (vs < 250 mg/kg as reported). Furthermore, the number of animals per group for the glucose and lipid profile experiments was five (vs seven as reported). The original article [1] has been updated. © The Author(s) 2022.

Instituciones: Universidad Peruana Cayetano Heredia